BioSpace News Archive

Allergan Foundation pledges $2,000,000 to support breast health research

Aldeyra Therapeutics, Inc. today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 12:35 PM ET at the Intercontinental Barclay Hotel, New York, NY.

InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New York.

Endo International plc today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level.

Life Sciences Ontario (LSO) applauds the Federal Government’s recommendations in its Health and Biosciences Economic Strategy Tables, released earlier this wee

Perrigo Company (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO Pharma A/S, and LEO Laboratories Limited.

Taiho Oncology today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib).*

Checkpoint Surgical, a privately held U.S. based medical device company with proprietary neurostimulation technology for nerve protection and repair, announced today the completion of an $8.8 million preferred series capital raise led by Mutual Capital Partners, a Cleveland based venture fund investing in rapidly growing, post-revenue technology businesses.

BioPharmX (NYSE American: BPMX) (the “Company”), a specialty pharmaceutical company developing products for the dermatology market, received a notice on September 24, 2018 from the NYSE American LLC (the “NYSE American”) that the Company is not in compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i)-(iii) of the NYSE American Company Guide.

Infusing the blood supply with new blood donors, strengthening inventory levels and helping to save lives